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ttps://doi.org/10.1016/j.jmoldx.2020.07.006The detection and characterization of cell-free DNA (cfDNA) in peripheral blood from neuroblastoma
patients may serve as a minimally invasive approach to liquid biopsy. Major challenges in the analysis of
cfDNA purified from blood samples are small sample volumes and low cfDNA concentrations. Droplet
digital PCR (ddPCR) is a technology suitable for analyzing low levels of cfDNA. Reported here are two
quadruplexed ddPCR assay protocols that reliably quantify MYCN and ALK copy numbers in a single
reaction together with the two reference genes, NAGK and AFF3, and accurately estimate ALKF1174L (exon
23 position 3522, C>A) and ALKR1275Q (exon 25 position 3824, G>A) mutant allele fractions using
cfDNA as input. The separation of positive and negative droplets was optimized for detecting two
targets in each ddPCR fluorescence channel by the adjustment of the probe and primer concentrations
of each target molecule. The quadruplexed assays were validated using a panel of 10 neuroblastoma cell
lines and paired blood plasma and primary neuroblastoma samples from nine patients. Accuracy and
sensitivity thresholds in quadruplexed assays corresponded well with those from the respective
duplexed assays. Presented are two robust quadruplexed ddPCR protocols applicable in the routine
clinical setting and that require only minimal plasma volumes for the assessment of MYCN and ALK
oncogene status. (J Mol Diagn 2020, 22: 1309e1323; https://doi.org/10.1016/j.jmoldx.2020.07.006)Supported by the BMBF/European Union through the Horizon2020
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Disclosures: None declared.Neuroblastoma, a neuroectodermally derived embryonic
tumor and the most common extracranial tumor of child-
hood, accounts for 11% of cancer-related deaths in children
world wide, mostly due to systemic and resistant relapses.1
It is characterized by a heterogeneous tumor biology and,
hence, clinical variability ranging from spontaneous
regression or localized, stable disease to rapid metasta-
sizing progression with a fatal outcome.2 The basic helix-
loop-helix transcription factor, N-myc proto-oncogene
protein (MYCN), regulates the migration, proliferation,
and differentiation of the neural crest progenitor cells.3
MYCN amplification occurs in approximately 25% ofPathology and American Society for Investiga
Y-NC-ND license (http://creativecommons.orgprimary human neuroblastomas to increase the rate of
DNA synthesis, promote cell cycle progression, and sup-
press differentiation.4 MYCN amplification is a strong
predictive biomarker for unfavorable patient survival,5 andtive Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
Peitz et alindirect approaches to target binding partners or down-
stream effectors of MYCN have yielded encouraging re-
sults.6 Recent data suggest that MYCN amplification can
exist at the (sub)clonal level, necessitating the use of bio-
sampling procedures and technologies with the capacity for
detecting these cell populations.7,8 Activating mutations in
the anaplastic lymphoma kinase gene (ALK ), occur in
approximately 10% of neuroblastomas, the most frequent
causing the F1174L and R1275Q substitutes in the receptor
tyrosine kinase domain.9e12 The resulting proteins are
auto-hyperphosphorylated and cause uncontrolled prolif-
eration. ALK-driven neuroblastomas, often relapses that
may have expanded from a single ALK-mutant clone,13 are
frequently resistant to chemo- and radiotherapy.9,10,14
Activating ALK mutations or amplifications have become
the first target in the treatment of neuroblastomas that is
directly druggable by small-molecule inhibitors as a
personalized medicine approach,15,16 necessitating contin-
uous molecular monitoring in patients with neuroblastoma
for potential (re)emergence of ALK mutant or amplified
clones. Clinical testing for ALK variants is performed using
a broad spectrum of methodologies, including next-
generation sequencing, targeted-panel sequencing, and
droplet digital (dd)ePCR. Gold standards for ALK di-
agnostics in routine clinical care are expected to evolve
within the framework of clinical trials, and are likely to
comprise two complementary untargeted and targeted
technologies applied, at least initially, in partially over-
lapping analyses for longitudinal patient monitoring to
keep costs affordable.
The invasive nature of surgical biopsies most often pre-
vents their sequential application in monitoring disease.
Single biopsies also fail to reflect cancer dynamics, intra-
tumor heterogeneity, and drug sensitivities that most likely
change during clonal evolution and under the selective
pressure of therapy. Peripheral blood has several compo-
nents that have been assessed for tumor-derived nucleic acid
content.17e19 Thus, longitudinal patient monitoring using
liquid biopsies may represent a promising strategy for
patient care, although caution should be exercised in
generalizing from the limited data available at this time.
ddPCR is a highly sensitive, recently developed technol-
ogy for quantifying specific regions.20,21 The ddPCR reaction
reagents are partitioned into 20,000 droplets before reactions
are allowed to proceed to the end plateau in individual
droplets; then droplets are classified as positive or negative
from their fluorescence signal intensity. Duplex ddPCR
protocols for detecting MYCN and ALK copy number status
in cell-free (cf)-DNA purified from patient plasma samples
have been previously established.22 Combaret et al23 pre-
sented ddPCR protocols for detecting ALKF1174L and
ALKR1275Q hotspot mutations, each together with the
respective wild-type sequence in duplex reactions. Here, the
blood sample volumes sequentially required from infants and
young children, the patients most often affected by
neuroblastoma, were minimized by the extension of1310multiplexing for the generation of robust quadruplexed
ddPCR protocols.Materials and Methods
Patient Samples
Paired blood plasma and fresh-frozen primary tumor
samples were collected from patients treated at
CharitéeUniversitätsmedizin Berlin (Berlin, Germany) or
provided by the German Neuroblastoma Biobank (Cologne,
Germany). All patients were registered with the German
NB2004 trial or the NB 2016 Registry, and informed pa-
tient/parent consent was obtained before trial participation.
Peripheral blood was centrifuged at 1900  g for 7 minutes
at Charité and at 1000  g for 10 minutes at the German
Neuroblastoma Biobank to separate plasma. After centrifu-
gation at 3250  g for 10 minutes to remove cell debris,
plasma was stored at 80C. The ALK copy number in
tumor samples was determined as a routine diagnostic
method using fluorescence in situ hybridization.Cell Culture
The BE(2)-C cell line was obtained from the European
Collection of Authenticated Cell Cultures (Salisbury, UK),
and Kelly and SH-SY5Y cell lines, from the Deutsche
Sammlung von Mikroorganismen und Zellkulturen
(Braunschweig, Germany). The CLB-GA [established in the
Centre Léon BERARD (CLB), Lyon, France24] as well as the
IMR-5, LAN-5, and LAN-6 cell lines were kindly gifted by
Johannes H. Schulte (CharitéeUniversitätsmedizin Berlin);
the NB-1 cell line, by Ina Oehme (German Cancer Research
Center, Heidelberg, Germany); and the SH-EP and SK-N-AS
cell lines, by Larissa Savelyeva (German Cancer Research
Center). Cell lines were authenticated by high-throughput
single-nucleotide polymorphismebased assays.25 Genomic
cell line characteristics are summarized in Supplemental Table
S1.9e12,26e46 The BE(2)-C, CLB-GA, SH-SY5Y, and SK-N-
AS cell lines were maintained in Dulbecco’s modified Eagle’s
medium (Lonza, Cologne, Germany) supplemented with 10%
fetal calf serum and 1% nonessential amino acids. The LAN-6
cell line was cultured in Dulbecco’s modified Eagle’s medium
supplemented with 20% fetal calf serum. The IMR-5, Kelly,
LAN-5, NB-1, and SH-EP cell lines were cultured in RPMI
1640 medium (Lonza) supplemented with 10% fetal calf
serum and 1% nonessential amino acids. All cell lines were
maintained at 37C and 5% CO2, and continuous culture was
avoided to maintain low passage numbers and to reduce the
risk for long-term culture-induced genomic alterations. Cells
for experiments were grown in short-term culture from
low-passage stock aliquots maintained in liquid nitrogen. All
cell lines were regularly monitored for infection with
Acholeplasma laidlawii, Mycoplasma spp, and squirrel mon-
key retrovirus using high-throughput, multiplexed testing.47jmdjournal.org - The Journal of Molecular Diagnostics
Molecular Monitoring for NeuroblastomaGenomic DNA and cfDNA Preparation
Genomic DNA (gDNA) was extracted from tumor tissues and
cell lines using the Puregene Core Kit A or the QIAamp DNA
Mini Kit (both from Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. gDNA from cell lines was
fragmented by sonication before ddPCR. Tumor DNA could
not be sonicated because of the small sample volumes (20 mL),
and fragmentation was achieved by adding 5 U of HindIII
restriction enzyme (New England BioLabs, Frankfurt am Main,
Germany) to each ddPCR reaction. Thawed plasma samples
were centrifuged at 2000 g for 5 minutes to clear debris, then
supernatants were centrifuged at 20,000  g for 5 minutes.
cfDNA was purified from a minimum of 200 mL of stored
plasma samples using the QIAamp Circulating Nucleic Acid
Kit (Qiagen), then concentrated to 50 mL using the DNA Clean
& Concentrator-5 kit (Zymo Research, Freiburg, Germany),
both according to the manufacturers’ directions. cfDNA did not
require fragmentation prior to ddPCR. Extracted DNA samples
were quantified on a Qubit 2.0 fluorometer (Life Technologies,
Darmstadt, Germany). The Cell-Free DNA ScreenTape assay
and the TapeStation 4200 system (both from Agilent Tech-
nologies, Santa Clara, CA) were used for DNA quality-control
samples according to the manufacturer’s instructions.
Droplet Digital PCR
The QX200 ddPCR System (Bio-Rad Laboratories, Munich,
Germany) was used for analyzing the copy number statuses of
MYCN (2p24.3), ALK (2p23.2 to 2p23.1), NAGK (2p13.3),
and AFF3 (2q11.2), and for detecting ALK F1174L (exon 23
position 3522, C>A) and R1275Q (exon 25 position 3824,
G>A) hotspot mutations with their corresponding wild-type
sequences. TaqMan ddPCR reaction mixtures contained the
2 ddPCR Supermix for Probes (no deoxyuridine triphos-
phate) (Bio-Rad Laboratories) and optimized primer and probe
concentrations (Tables 1 and 2)23,48 in a total volume of
20 mL. Primer3 software version 0.4.0 was used for primer and
probe design.49 To confirm the specificity of the probes used
for the detection of ALKF1174L (3522, C>A) and ALKR1275Q
(3824, G>A), four double-stranded synthetic ALK templates
with the following sequences were generated (Metabion, Pla-
negg, Germany): ALKF1174L (3522, C>A, TTC>TTA), 50-GC
CCAGACTCAGCTCAGTTAATTTTGGTTACATCCCTC
TCTGCTCTGCAGCAAATTAAACCACCAGAACATTGTT
CGCTGCATTGGGG-30; ALKF1174L (3522, C>G, TTC>T
TG), 50-GCCCAGACTCAGCTCAGTTAATTTTGGTTACAT
CCCTCTCTGCTCTGCAGCAAATTGAACCACCAGAA-




(3824, G>T, CGA>CTA), 50-GTCCAGGCCCTGGAA-
GAGTGGCCAAGATTGGAGACTTCGGGATGGCCCTA-
GACATCTACAGGTGAGTAAAGACTGCCTCACCCC-30.
The probe established for the detection of ALKF1174L (3522,The Journal of Molecular Diagnostics - jmdjournal.orgC>A) reliably detected this but not the ALKF1174L (3522,
C>G) mutation. The probe established for the detection of
ALKR1275Q (3824, G>A) detected only this and not the
ALKR1275L (3824, G>T) mutation (Supplemental
Figure S1), together confirming the specificity of the
probes selected.
Reaction mixtures were loaded into droplet generator car-
tridges together with 70 mL Droplet Generation Oil (both from
Bio-Rad). Droplets were generated in the QX200 droplet
generator, and manually transferred into a 96-well PCR plate
(Eppendorf, Hamburg, Germany) according to the manufac-
turer’s recommendations. The PCR plate was heat-sealed with
the PX1 Plate Sealer (Bio-Rad), and PCR reactions were per-
formed on a T100 thermocycler (Bio-Rad), with the following
programs for copy number variations: denaturation at 95C for
10 minutes, 40 cycles of 30 seconds at 94C and 1 minute at
58C, and final denaturation for 10 minutes at 98C; and for
ALK hotspot mutation analysis: denaturation at 95C for
10 minutes, 40 cycles of 30 seconds at 94C and 1 minute at
62.5C, and final denaturation for 10 minutes at 98C. Droplet
reaction end points were assessed in the QX200 ddPCR
Droplet Reader. Target gene copy numbers and mutant allele
fractions (MAFs) were analyzed using QuantaSoft Analysis
software version 1.7.4.0917 and QuantaSoft Analysis Pro
software version 1.0.596 (Bio-Rad). All multiplex ddPCR
assays contained appropriate nontemplate, positive and nega-
tive controls in each run to allow the software programs to
generate specific thresholds.
The QuantaSoft Analysis software used for duplex
ddPCR assays determined the copy number by calculating
the ratio of target molecule concentration, A (copies/mL), to
the reference molecule concentration, B (copies/mL),
multiplied by the number of reference species copies, NB, in
the human genome (Copy number Z A/B $ NB). The
QuantaSoft Analysis Pro software used triplex and quad-
ruplex ddPCR assays for determining the copy number by
calculating the ratio of the target molecule concentration, A,
to the geometric mean of the reference molecule concen-
trations, B (copies/mL) and C (copies/mL), multiplied by the
number of reference species copies, NB, (Copy number Z
A/[geomean(B,C )] $ NB). MYCN and ALK amplifications
were designated as the detection of 8.01 copies, with gain
(defined as the detection of 2.74 to 8.00 copies) and normal
diploid status (defined as the detection of 1.50 to 2.73
copies).22 The false-positive rate and lower limit of detec-
tion for point mutation analyses were calculated with Bio-
Rad lookup tables in line with the model by Armbruster
and Pry.50 In principle, false-positive rate calculation was
based on two parameters. The number of false-positive
droplets and the minimally required concentration of
mutant target molecules (copies/mL) for each point-mutation
protocol were defined by analysis of gDNA from cell lines
with the wild-type sequence of the respective mutation. A
sample was scored as positive if both the number of droplets
detecting the mutation and the concentration of mutant
target molecules (copies/mL) were above the set thresholds.1311




Duplex ddPCR Triplex ddPCR Quadruplex ddPCR
AFF3-for 50-CACCTAGCATGTGTGGCATT-30 900 900 900
AFF3-rev 50-GCAGATCCAGGTCGTTGAAG-30 900 900 900
AFF3-probe 50-HEX-AACAACTCTTTCTGTCCCCCT-BHQ1-30 250 125 125
ALK-for 50-CTTGTCCTCTGACTCTTCTCG-30 900 900 300
ALK-rev 50-CAAGACTCCACGAATGAGC-30 900 900 300
ALK-probe 50-FAM-TCACAGCTCCGAATGTCCTG-BHQ1-30 250 250 360
MYCN-for* 50-GTGCTCTCCAATTCTCGCCT-30 900 900 450
MYCN-rev* 50-GATGGCCTAGAGGAGGGCT-30 900 900 450
MYCN-probe* 50-FAM-CACTAAAGTTCCTTCCACCCTCTCCT-BHQ1-30 250 250 125
NAGK-for* 50-TGGGCAGACACATCGTAGCA-30 900 900 900
NAGK-rev* 50-CACCTTCACTCCCACCTCAAC-30 900 900 900
NAGK-probe* 50-HEX-TGTTGCCCGAGATTGACCCGGT-BHQ1-30 250 350 350
*Adapted from Gotoh et al.48
FAM, 6-carboxyfluorescein; HEX, hexachloro-fluorescein.
Peitz et alThe lower limit of detection was determined for each assay
by measuring a 1:10 to 1:100,000 mix of DNA derived from
cell lines with (SH-EP, CLB-GA) or without (SK-N-AS) the
respective mutations. Thresholds were separately calculated
for 0.5, 2, 10, 20, 80, and 130 ng of input DNA in duplex
and quadruplex formats.WES of Matched cfDNA and Tumor Samples
Whole-exome sequencing (WES) libraries were prepared
with the Agilent SureSelect XT kit version 6 (Agilent
Technologies) according to the manufacturer’s protocol. For
sequencing, four to five libraries were pooled in the flow
cell to be sequenced (100-bp, paired-end) in one lane on the
HiSeq 4000 sequencer (Illumina, San Diego, CA), with a
median of 84 million fragments per sample. Standard
quality control was performed using FastQC version 0.11.9
(http://bioinformatics.babraham.ac.uk/projects/fastqc, last
accessed February 20, 2020). Reads were aligned to theTable 2 Sequences and Concentrations of Primers and Probes Used in




ALKF1174L probe, FAM 50-FAM-TCTCTGCTCTGCAGCAAATTAA
ALK1174 probe, FAM 50-FAM-TCTCTGCTCTGCAGCAAATTCA
ALK1174 probe, HEX 50-HEX-TCTCTGCTCTGCAGCAAATTCA
ALK1275-for 50-GTCCAGGCCCTGGAAGAG-30
ALK1275-rev 50-GGGGTGAGGCAGTCTTTACTC-30
ALKR1275Q probe, FAM 50-FAM-TTCGGGATGGCCCAAGACAT-B
ALKR1275Q probe, HEX 50-HEX-TTCGGGATGGCCCAAGACAT-B
ALK1275 probe, HEX 50-HEX-TTCGGGATGGCCCGAGACAT-B
*Adapted from Combaret et al.23
FAM, 6-carboxyfluorescein; HEX, hexachloro-fluorescein.
1312GRCh37 reference sequence using BWA-MEM software
version 0.7.15.51 Separate read groups were assigned for all
reads from one lane, and duplicates were masked using
Samblaster software version 0.1.24.52 MYCN and ALK copy
numbers were estimated using CNVkit53 version 0.9.6 on
each WES library without a normal control, as described by
the manufacturer. Digital copy numbers in tumor samples
were calculated as (2 $ 2log2FC e 2 þ 2 $ p)/p. The log2 fold-
change, Log2FC, of a given gene was estimated to a diploid
baseline by CNVkit, and p was the tumor cell content.
Tumor samples had at least 70% tumor cells. Copy numbers
derived from cfDNA analysis were calculated by setting the
tumor cell content to 1.WES of Neuroblastoma Cell Lines
DNA was extracted from the human neuroblastoma cell lines
BE(2)-C, Kelly, LAN-6, and SH-SY5Y using the NucleoSpin
Tissue kit (Macherey-Nagel, Düren, Germany) according toMultiplexed ddPCR Protocols to Detect the Neuroblastoma-Specific
Concentration, nmol/L
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Molecular Monitoring for Neuroblastomathe manufacturer’s instructions. Libraries for WES were pre-
pared using the SureSelect Human All Exon kit version
7 (Agilent) and the TruSeq Exome kit (Illumina). Libraries
were sequenced onHiSeq 4000 andNovaSeq 6000 sequencers
(Illumina). Read sequences and base quality scores were
demultiplexed and stored in FASTQ format using bcl2fastq
software version 2.20 (Illumina). Adapter remnants and low-
quality read ends were trimmed off using custom scripts. The
quality of the sequence reads was assessed using FastQC
software. Reads were aligned to the human genome, assembly
GRCh38, using BWA-MEM software,51 and duplicate read
alignments were removed using Samblaster.52 Copy number
variationswere determined using CNVkit.53 Single-nucleotide
variants were identified using Strelka2 software version
2.9.10.54 Potential germline variants were filtered out by
excluding all single-nucleotide variants that had also been
observed in at least 1% of samples in cohorts of healthy in-
dividuals, namely the 1000 Genomes Project55 and the Na-
tional Heart, Lung, and Blood Institute’s Grand Opportunity
Exome Sequencing Project56 cohorts.
Statistical Analysis
Correlation analyses were performed using GraphPad Prism
software version 6.00 (GraphPad Software, San Diego, CA).
P values  0.05 were considered significant.
Results
Developing Quadruplexing to Absolutely Quantify MYCN
and ALK Copy Numbers in a Single ddPCR Assay
Duplex ddPCR assay conditions were previously reported to
assess MYCN and ALK copy numbers in gDNA and cfDNA
usingN-acetylglucosamine kinase gene (NAGK) as a reference
gene.22 To save sample volume, which is substantially
restricted in infancy and early childhood, a quadruplex ddPCR
assay was established for reliable measurement of both gene
copy numbers in a single reaction together with two reference
genes to increase robustness for normalization. Assay condi-
tions for a triplex reaction were first established, in which
MYCN or ALK was measured in parallel in channel 1 while
NAGK and a second reference gene,AFF3, which is frequently
used as a control for fluorescence in situ hybridization directed
againstMYCN,57 were both detected in channel 2. For accurate
discrimination between fluorescence amplitudes of negative,
single-positive, and double-positive droplet clusters for AFF3
and NAGK in channel 2, a uniplex reaction was performed
using fragmentedDNA from the SK-N-AS neuroblastoma cell
line as a template, in which AFF3 and NAGK probe concen-
tration series ranging from 100 to 400 nmol/L together with a
fixed primer concentration of 900 nmol/L for both genes were
tested. Optimal separation of AFF3-positive and NAGK-posi-
tive droplet clusters and identical fluorescence amplitude of
AFF3-negative and NAGK-negative droplet clusters as the
desired result were used for selecting probe concentrations ofThe Journal of Molecular Diagnostics - jmdjournal.org125 nmol/L (AFF3) and 350 nmol/L (NAGK) for further
testing in triplex reactions with these settings (Supplemental
Figure S2). Using fragmented DNA from SK-N-AS cells as
a template and the previously established primer and probe
concentrations for ALK and MYCN for duplex reactions
(Table 1),22 triplex reactions (ALK/AFF3/NAGK, MYCN/
AFF3/NAGK) were performed and an accurate separation of
negative and single-, double-, and triple-positive droplet
clusters with ALK or MYCN in channel 1 and both AFF3 and
NAGK in channel 2 were observed (Figure 1).
Probe and primer concentrations for the simultaneous
detection ofALK andMYCN in channel 1were next established
using fragmented SK-N-AS gDNA as a template. Probes for
ALK and MYCN were each tested in the range of 100 to 400
nmol/L in combination with the standard primer concentration
(900 nmol/L) for duplex and triplex assays (Table 1) in a
uniplex assay. The ALK probe concentration of 400 nmol/L
and two MYCN probe concentrations (125 and 250 nmol/L)
were further tested in MYCN/AFF3 and ALK/NAGK duplex
reactions (Supplemental Figure S3A). Finalizing conditions
were used for absolutely quantifyingMYCN copy number, and
the two probe concentrations were combined, with primer
concentrations varying between 225 and 900 nmol/L. Positive
and negative droplet clusters were optimally separated using
probe and primer concentrations of 125 and 450 nmol/L,
respectively, as: i) the bandwidths of both clusters were
comparatively smallest, ii) the distance between both clusters
was comparatively largest, and iii) the fluorescence amplitudes
of MYCN-negative and ALK-negative droplet clusters were
almost identical (Supplemental Figure S3B). The assay con-
ditions were then optimized to absolutely quantify ALK copy
numbers. The probe range of 350 to 400 nmol/L was tested
with 300 or 900 nmol/L primer in theMYCN/AFF3 and ALK/
NAGK duplex reactions. While ALK-positive and ALK-nega-
tive droplet clusters were clearly separable with each of the
probe/primer combinations tested, 300 nmol/L primer with
probe concentrations between 360 and 380 nmol/L was most
suited for simultaneousALK andMYCN detection in channel 1
(Supplemental Figure S4A). All three ALK-specific probe
concentrations produced separation of negative and single-,
double-, triple-, and quadruple-positive clusters in the ALK/
MYCN/AFF3/NAGK quadruplex reaction, but with varying
degrees of droplet rain between the ALK and MYCN double-
positive cluster. The ALK single-positive cluster in channel 1
was smallest with 360 nmol/L ALK probe, prompting its se-
lection as the optimized concentration (Supplemental
Figure S4, BeD). QuantaSoft Analysis Pro software accu-
rately distinguished a total of 16 different droplet clusters
including negative and single-, double-, triple- and quadruple-
positive droplets from the two-dimensional plot (Figure 2A
and Table 1). Findings from channels 1 and 2 were confirmed
in one-dimensional plots (Figure 2, B and C) and histograms
(Figure 2, D and E).
The accuracy and sensitivity of the quadruplex ddPCR
reaction was compared to those of the triplex and previously
published duplex reactions using fragmented SK-N-AS1313
Figure 1 Representative two-dimensional plots of triplex ddPCR assays assessing ALK and MYCN copy number status. Genomic DNA was extracted from SK-N-AS
cells and fragmented by sonication before ddPCR reactions using a total of 20 ng as input material. Channel 1 fluorescence (6-carboxyfluorescein; FAM) was
plotted against channel 2 fluorescence (hexachloro-fluorescein; HEX) for each droplet in the triplex reactions. A and B: ALK (A) and MYCN (B) copy numbers were
detected in channel 1, and the normal diploid reference genes, AFF3 and NAGK, were measured in channel 2. Circles indicate individual droplet clusters.
Peitz et algDNA as a template in a dilution series from 0.5 to 100 ng.22
Detected and assigned MYCN, ALK, NAGK, and AFF3
concentrations were significantly and comparably correlated
in all assay types (Pearson correlation coefficient, >0.99 for
all four DNA targets in all assay types) (Supplemental
Figure S5). These data demonstrate that the quadruplex re-
actions maintain the same linearity as triplex and duplex re-
actions within the range 0.5 to 100 ng template for the
absolute quantification of MYCN and ALK copy numbers
using AFF3 and NAGK as reference genes.
Quadruplex ddPCR Can Quantify MYCN and ALK Copy
Numbers in Cell Lines
Eight previously analyzed neuroblastoma cell lines known
to harbor MYCN and/or ALK amplification, gain, or normal
diploid chromosomal complements for comparative re-
analysis in duplex, triplex, and quadruplex reactions were
selected.22 In cell lines known to harbor MYCN amplifica-
tions, quadruplex ddPCR quantified MYCN copy numbers
ranging from 109.9 to 504.8 copies, which corresponded1314well with copy numbers quantified in triplex (109.3 to
542.6) and duplex (106.2 to 530.8) assays (Figure 3A).
Absolute MYCN copy numbers in the Kelly cell line were
higher in quadruplex (521.3) and triplex (596.6) reactions
than in duplex reactions (385.4) (Figure 3A), which was
most likely due to the modified normalization procedure
introduced by the second reference gene in quadruplex and
triplex reactions. Quadruplex ddPCR confirmed MYCN
gains in SH-SY5Y (3.13) and LAN-6 cells (3.18), and copy
numbers corresponded well with MYCN copy numbers
assessed by triplex and duplex reactions (Figure 3A).
Quadruplex (1.99  0.11), triplex (1.73  0.11), and duplex
(1.73  0.08) ddPCR reliably detected the normal diploid
MYCN status in the SK-N-AS cell line (Figure 3A). Quad-
ruplex (87.8), triplex (85.1), and duplex (87.4) ddPCR also
quantified the ALK amplification in the NB-1 cell line, and
ALK gains in the BE(2)-C, Kelly, SH-SY5Y, and LAN-6
cell lines (Figure 3B). ALK copy numbers ranged between
2.74 and 4.05 in the quadruplex format, between 2.92 and
4.49 in triplex format, and between 2.92 and 5.35 in the
duplex format. Absolute ALK copy numbers in the Kellyjmdjournal.org - The Journal of Molecular Diagnostics
Figure 2 Representative plots and histograms of quadruplex ddPCR assay assessing ALK and MYCN copy number status. Genomic DNA was extracted from
SK-N-AS cells and fragmented by sonication before ddPCR reactions using a total of 10 ng as input material. A: Representative two-dimensional plot of droplet
fluorescence in the quadruplex reaction. MYCN and ALK droplets were plotted in channel 1 (6-carboxyfluorescein; FAM) against AFF3 and NAGK droplets in
channel 2 (hexachloro-fluorescein; HEX). Lines indicate thresholds for negative as well as single-, double-, triple-, and quadruple-positive droplet clusters. B
and C: One-dimensional plots of droplet fluorescence in channel 1 for MYCN and ALK (B) and in channel 2 for AFF3 and NAGK (C). Plots document optimal
separation of negative, single-positive, and double-positive droplets. Blue dots (channel 1) and green dots (channel 2) indicate positive droplets; gray dots
indicate negative droplets. D and E: One-dimensional fluorescence amplitude histograms indicate the droplet frequency at specific fluorescence amplitudes in
channel 1 (D, MYCN and ALK ) and in channel 2 (E, AFF3 and NAGK ). Again, droplet frequencies for negative, single-positive, and double-positive clusters were
clearly distinguishable.
Molecular Monitoring for Neuroblastomacell line were, with 4.32 and 4.27 in the quadruplex and
triplex assays, slightly higher than the 3.0 measured in the
duplex assay (Figure 3B), most likely again reflecting the
more robust normalization in the quadruplex and triplex
assay designs. Normal ALK diploid status was detected in
the LAN-5, IMR-5, and SK-N-AS cell lines (Figure 3B).
Copy numbers ranged from 1.99  0.13 to 2.10  0.05
using the quadruplex protocol, which corresponded well
with those determined using triplex (1.93  0.24 to
2.13  0.15) and duplex (1.85  0.37 to 2.00  0.25)
protocols. For comparison, WES data were generated for the
BE(2)-C, Kelly, SH-SY5Y, and LAN-6 cell lines and copy
number variations were determined on the p-arm of chro-
mosome 2. This analysis showed a strong focal amplifica-
tion of the MYCN gene locus in the BE(2)-C and Kelly cells
(Supplemental Figure S6). Further, the Kelly, SH-SY5Y,
and LAN-6 cells showed widespread, albeit weaker, copy
number gains, up to four copies in total, in the first 50The Journal of Molecular Diagnostics - jmdjournal.orgmegabases of chromosome 2 that include the ALK gene
locus (Supplemental Figure S6), thus validating the ddPCR
results. Interestingly, the WES data showed a loss of het-
erozygosity in the AFF3 gene in the Kelly cell line, which
explains the different MYCN and ALK copy number results
obtained in those ddPCR assays that included AFF3 as a
second reference gene in the calculation. The data demon-
strate robust MYCN and ALK copy number quantification
that clearly distinguishes between amplification, gain, and
diploid allele status by the quadruplex ddPCR assay.
Quadruplex ddPCR Can Quantify MYCN and ALK Copy
Numbers from Blood Plasma or Neuroblastoma Samples
from Patients
Quadruplex ddPCR-based MYCN and ALK copy numbers
were next assessed in blood plasma samples pairedwith gDNA
from the corresponding primary neuroblastoma from three1315
Figure 3 Comparison of absolute MYCN and ALK copy numbers determined by multiplexed ddPCR assays in neuroblastoma cell lines. A and B: Genomic DNA
was extracted and fragmented by sonication before ddPCR reactions to quantify MYCN (A) and ALK (B) copy numbers. A total of 2 ng of DNA was used as input
material. Data are expressed as means  SD. n  3.
Peitz et alpatients. Results were compared with copy numbers deter-
mined by duplex and triplex ddPCR and re-analyzed from
WES data, which were deposited in the European Genome-
Phenome Archive (accession number EGAS00001004275;
https://www.ebi.ac.uk/ega/studies, last accessed March 2,
2020). Quadruplex ddPCR of tumor DNA revealed high-
level MYCN amplifications in samples from Patients 1 and 2,
which were confirmed by duplex and triplex ddPCR reactions
and re-analysis of WES tumor data (Table 3). All multiplexed
ddPCR assays detected theMYCN amplification using cfDNA
in plasma from Patients 1 and 2, although the copy numbers
estimated were consistently lower than those from direct
assessment of tumor DNA (Table 3). Findings were confirmed
through re-analysis of WES data from these cfDNA samples
(Table 3). The lower copy numbers detected in circulating
cfDNA may have stemmed from a dilution effect caused by
handling-induced damage to white blood cells in the samples
(these blood samples were previously collected for a different
purpose) from tumor heterogeneity or cfDNA derived from
nontumor cells. Therefore, the DNA quality was evaluated in
plasma samples from Patients 1 and 2 using the TapeStation
4200 System. The cfDNA content amounted to 69.8% and 81.
1% in these samples, thus pointing either to tumor heteroge-
neity or the presence of cfDNA derived from nontumor cells
(Table 3). Diploid MYCN allele status was detected by quad-
ruplex ddPCRusing either tumor or cfDNA fromPatient 3, and
was confirmed by all other assays (Table 3). Quadruplex
ddPCR detected an ALK gain using either tumor or cfDNA
from Patient 1 and diploid ALK allele status in Patients 2 and 3
using either DNA source (Table 3). Although the ALK gain
could not be clearly identified in theWES data, all other results
were confirmed in all other assays (Table 3). ALK fluorescent
in situ hybridization was performed on interphase nuclei of a
tumor section from Patient 1 and detected three ALK copies
(Supplemental Figure S7), thus confirming the ddPCR data
and a false-negative result in the WES data. The data1316consistently demonstrate that absolute MYCN and ALK copy
numbers can be quantified from DNA derived from either
tumor or plasma samples from patients, and that quadruplexed
ddPCR using two diploid reference genes for normalization is
a feasible and sensitive alternative for reducing sample
volumes.
Developing Quadruplex ddPCReBased Detection of
ALKF1174L and ALKR1275Q Hotspot Mutations
The ALK hotspot mutations at F1174 (C>A conversion at
nucleotide 3522 in exon 23) and R1275 (G>A conversion at
nucleotide 3824 in exon 25) occurring in neuroblastomas
can be detected by duplex ddPCR.23 It was hypothesized
that simultaneous detection of both ALK hotspot mutations
in a quadruplex ddPCR reaction is technically feasible. As
template providing both hotspot mutations and the wild-type
ALK sequences to develop the quadruplex assay, DNA was
extracted from the SH-EP neuroblastoma cell line
(harboring a heterozygous ALKF1174L mutation) and mixed
1:1 with DNA extracted from the CLB-GA neuroblastoma
cell line (harboring a heterozygous ALKR1275Q mutation).
Uniplex and duplex assays determined that 900 and 600
nmol/L primers with 350 and 400 nmol/L probes concen-
trations were optimal for detecting ALKF1174L and
ALKR1275Q target molecules, respectively, in channel 1
(Table 2). Both mutation sites in the wild-type sequence
were targeted (ALK1174 and ALK1275) to detect wild-type
ALK, with both clearly detected in channel 2 using 900
and 600 nmol/L primers and 50 and 150 nmol/L probes,
respectively (Table 2). Combining ALKF1174L and
ALKR1275Q detection in channel 1 with ALK1174 and
ALK1275 detection in channel 2 in a quadruplex reaction
allowed no clear identification of individual droplet clusters
(data not shown), prompting the application of the concept
of an inverted ddPCR protocol described by Alcaide et al.58jmdjournal.org - The Journal of Molecular Diagnostics





















1 M gDNA 75 d 290.6 239.2 233.9 239.7 3.24 2.80 2.89 2.30
cfDNA d 69.8 43.5 48.7 48.9 58.3 3.00 2.89 3.35 2.13
2 M gDNA 70 d 140.1 135.0 141.4 142.6 2.07 1.97 2.17 1.81
cfDNA d 81.1 32.3 36.1 35.1 37.9 1.96 2.40 2.26 1.88
3 M gDNA 90 d 1.86 1.82 1.64 1.92 2.05 2.17 1.78 1.92
cfDNA d n.a. 2.23 2.68 2.15 1.91 1.70 2.41 2.38 1.91
*DNA input for ddPCR reactions ranged from 1 to 2 ng.
yDNA input for WES ranged from 8 to 110 ng.
cfDNA, cell-free DNA; gDNA, genomic DNA; n.a., not analyzed; WES, whole-exome sequencing.
Molecular Monitoring for NeuroblastomaThe hexachloro-fluorescein fluorophore on the ALK1174
probe was replaced by a 6-carboxyfluorescein fluorophore,
and the 6-carboxyfluorescein fluorophore on the ALKR1275Q
probe was replaced by a hexachloro-fluorescein fluorophore
for the simultaneous detection of ALKF1174L and ALK1174 in
channel 1 and ALKR1275Q and ALK1275 in channel 2. This
approach produced accurate separation of negative, single-
positive, and double-positive droplet clusters including
ALKF1174L/ALK1275, ALK1174/ALK1275, ALKF1174L/ALKR1275Q,
and ALK1174/ALKR1275Q (Figure 4A). In line with data from
previous reports on other inverted ddPCR approaches,57 some
double-double positive clusters (ALKF1174L/ALK1174 in channel
1 and ALKR1275Q/ALK1275 in channel 2) as well as triple-
positive and quadruple-positive droplets were not clearly
separable from other droplet clusters (Figure 4A). Findings
from channels 1 and 2 were confirmed in one-dimensional
plots (Figure 4, B and C) and histograms (Figure 4, D and
E). The data demonstrate that an inverted quadruplex ddPCR
approach can be used for analyzing the neuroblastoma-specific
ALKF1174L and ALKR1275Q hotspot mutations in a single
reaction.
The dynamic range of the ALKF1174L/ALKR1275Q quad-
ruplex ddPCR detection was assessed using serially diluted
DNA template (0.5 to 130 ng) from the SK-N-AS, SH-EP, or
CLB-GA cell line. The detected concentrations of target
molecules (ALKF1174L, ALKR1275Q, ALK1174, and ALK1275)
were significantly correlated with the theoretically assigned
concentrations (Pearson correlation coefficients ranged from
0.9942 to 0.9981) and strongly resembled the concentrations
detected in duplex reactions (ALKF1174L/ALK1174 and
ALKR1275Q/ALK1275), with Pearson correlation coefficients
ranging from 0.9871 to 0.9981 (Supplemental Figure S8).
The data demonstrate that quadruplex ALKF1174L and
ALKR1275Q hotspot mutation detection remains linear within
the range of 0.5 to 130 ng of input DNA.
Sensitivity thresholds for ALK hotspot mutation detec-
tion in quadruplex reactions were also defined and
compared to sensitivity in duplex detection. DNA from
cell lines harboring either ALK hotspot mutation was
mixed 1:10 to 1:100,000 with DNA from cell lines with
homozygous wild-type ALK. Mutant allele fractionsThe Journal of Molecular Diagnostics - jmdjournal.org(MAFs) were designated as 0% in cells with wild-type
ALK. A neuroblastoma cell was categorized as harboring
an ALKF1174L mutation using the following thresholds: 4
positive droplets and at least 0.31 copies/mL for up to
10 ng of input DNA and 5 positive droplets and at least
0.57 copies/mL for higher input DNA amounts. These
thresholds were very similar to those defined for
the duplex reaction (4 positive droplets, at least 0.33
copies/mL). The thresholds for categorizing a neuroblas-
toma cell as harboring an ALKR1275Q mutation varied ac-
cording to input DNA amounts in both assays (quadruplex
reaction, 5 to 15 positive droplets, 0.42 to 1.34 copies/
mL; duplex reaction, 4 to 17 positive droplets, 0.32 to
1.31 copies/mL). Together, the sensitivity thresholds for
the simultaneous detection of both neuroblastoma-specific
ALK hotspot mutations in quadruplex ddPCR were similar
to those for the respective duplex ddPCR reactions.
Quadruplex ddPCR Correctly Assesses ALKF1174L and
ALKR1275Q MAFs in Cell Lines
The quadruplex ddPCR assay for ALK hotspot mutations
was tested in a panel of six neuroblastoma cell lines
harboring the ALKF1174L mutation (SH-EP, Kelly12,34),
the ALKR1275Q mutation (CLB-GA, LAN-510,11), or wild-
type ALK [SK-N-AS, BE(2)-C12]. The ALKF1174L muta-
tion was correctly detected in SH-EP and Kelly cells,
and MAFs determined using quadruplex ddPCR corre-
sponded well those determined by duplex ddPCR
(Table 4). Both quadruplex and duplex ddPCR correctly
detected MAFs indicating that only one allele harbored
the mutation. Wild-type ALK in both alleles was
correctly detected in CLB-GA, LAN-5, SK-N-AS, and
BE(2)-C cells using the ALK1174 target in quadruplex
ddPCR (Table 4). The monoallelic ALKR1275Q mutation
was similarly detected in CLB-GA and LAN-5 cells,
with strongly corresponding MAFs detected by quad-
ruplex and duplex ddPCR assays (Table 4). The single
wild-type ALK allele in SH-EP and Kelly cells and the
biallelic wild-type ALK status in SK-N-AS and BE(2)-C
cells were correctly detected using the ALK1275 target in1317
Figure 4 Quadruplex ddPCR assay for the detection of the neuroblastoma-specific hotspot mutations ALKF1174L and ALKR1275Q. For assay design, DNA was
extracted from SH-EP (ALKF1174L) and CLB-GA (ALKR1275Q) cells, fragmented by sonication and mixed 1:1 before ddPCR reactions to generate a DNA mixture
comprising both mutations. A total of 20 ng of this DNA mixture was used as input material. A: Representative two-dimensional plot of droplet fluorescence.
ALKF1174L and ALK1174 droplets were plotted in channel 1 (6-carboxyfluorescein; FAM) against ALKR1275Q and ALK1275 droplets in channel 2 (hexachloro-
fluorescein; HEX). Shown are negative, single-positive, and double-positive clusters. B and C: One-dimensional plots of droplet fluorescence for ALKF1174L and
ALK1174 in channel 1 (B) and for ALKR1275Q and ALK1275 in channel 2 (C). Plots documented optimal separation of negative and single-positive droplets. Blue
dots (channel 1) and green dots (channel 2) indicate positive droplets; gray dots indicate negative droplets. D and E: One-dimensional fluorescence
amplitude histograms indicate the droplet frequency at specific fluorescence amplitudes in channel 1 (D, ALKF1174L and ALK1174) and in channel 2 (E, ALKR1275Q
and ALK1275). Droplet frequencies are clearly distinguishable.
Peitz et alquadruplex ddPCR (Table 4). These findings suggest that
quadruplex ddPCR performs well as an assay-validating
step in the detection of wild-type ALK and ALK hotspot
mutations in neuroblastoma cell lines.
Quadruplex ddPCR Detects ALKF1174L and ALKR1275Q
MAFs in Blood Plasma and Neuroblastoma Samples
from Patients
After quadruplex ddPCR was validated in the detection of
neuroblastoma-specific ALK hotspot mutations in cell
lines, the assay was applied to paired blood plasma and
tumor samples from six patients with neuroblastoma to
compare its accuracy and sensitivity to those of the
established duplex ddPCR reactions23 using both standard
tumor biopsies and liquid biopsies suited to longitudinal
patient monitoring. The quadruplex ddPCR correctly
detected an ALKF1174L mutation in tumor and plasma1318samples from Patients 4 and 5, with MAFs indicating that a
varying proportion of tumor cells harbored the mutation on
one allele (although 14% higher in quadruplex detection in
cfDNA from Patient 4) (Table 5). No ALKF1174L mutation
was detected in matched tumor-derived DNA/cfDNA
samples from Patients 6 through 9 by either assay
(Table 5). The quadruplex ddPCR assay correctly
demonstrated an ALKR1275Q mutation in tumor-derived
DNA and plasma-derived cfDNA from Patients 6 to 8,
and the MAFs obtained by the two assays very closely
resembled each other in all cases except one, which was a
10% higher MAF measured in tumor-derived DNA from
Patient 8 by quadruplex ddPCR (Table 5). No ALKR1275Q
mutation was detected in matched tumor/blood plasma
samples from Patients 4, 5, or 9 by either assay (Table 5).
The higher MAFs in cfDNA from Patient 4 and tumor-
derived DNA from Patient 8, as determined by quad-
ruplex ddPCR compared to duplex ddPCR, prompted thejmdjournal.org - The Journal of Molecular Diagnostics
Table 4 Comparison of Multiplexed ddPCR Assays for Detecting ALKF1174L and ALKR1275Q Mutant Allele Fractions in Neuroblastoma Cell Lines
Cell line*
ALKF1174L (3522, C>A)y ALKR1275Q (3824, G>A)y
Quadruplex ddPCR Duplex ddPCR Quadruplex ddPCR Duplex ddPCR
SH-EP 45.82  0.87 48.64  0.31 0 0
Kelly 31.58  0.69 31.20  0.52 0 0
CLB-GA 0 0 53.77  0.52 53.04  0.64
LAN-5 0 0 53.55  1.95 51.45  0.82
SK-N-AS 0 0 0 0
BE(2)-C 0 0 0 0
*DNA input, 10 ng.
yMutant allele fraction is shown in mean percentage  SD for n  3 replicates; mutant allele fraction of 0% indicates wild-type ALK.
Molecular Monitoring for Neuroblastomatesting of the influence of input quantity on MAF mea-
surement, as the two respective samples contained higher
DNA amounts than all other samples analyzed. Frag-
mented DNA was serially diluted from an ALKF1174L
mutant cell line (SH-EP) and an ALKR1275Q mutant cell line
(CLB-GA) in H2O to obtain 0.5, 2, 10, 20, 80, and 130 ng
of DNA. ALKF1174L MAF assessment based on 0.5 to 20
ng of total input DNA resulted in similar findings in
quadruplex and duplex reactions. Using DNA input
amounts of 80 and 130 ng resulted in comparatively higher
MAF results in the quadruplex reaction (Supplemental
Figure S9A). Similar findings were obtained on analysis
of the ALKR1275Q MAF with varying DNA input amounts.
Using 0.5 to 20 ng of DNA input, MAF results were
similar in the quadruplex and duplex reactions, but were
higher in the quadruplex reaction with total input DNA
amounts of 80 and 130 ng (Supplemental Figure S9B).
This observation was likely due to the underestimation of
an increasing amount of wild-type and mutant double-
positive droplets in higher DNA input samples inTable 5 Comparatively Determined ALKF1174L and ALKR1275Q















4 gDNA 48.17 48.36 0 0
cfDNA 59.29 45.40 0 0
5 gDNA 11.07 12.95 0 0
cfDNA 36.27 35.20 0 0
6 gDNA 0 0 47.92 48.19
cfDNA 0 0 32.91 28.90
7 gDNA 0 0 43.48 43.65
cfDNA 0 0 21.99 22.10
8 gDNA 0 0 87.29 77.96
cfDNA 0 0 71.90 68.00
9 gDNA 0 0 0 0
cfDNA 0 0 0 0
*Cell-free DNA input material ranged between 6.9 and 72.6 ng, and gDNA
input material ranged between 6.9 and 98.5 ng.
yMutant allele fraction of 0% indicates wild-type ALK.
cfDNA, cell-free DNA; gDNA, genomic DNA.
The Journal of Molecular Diagnostics - jmdjournal.orginverted ddPCR protocols because the fluorescence signals
of double-positive droplets had an amplitude similar to that
of single mutant-positive droplets and might have been
obscured in this droplet cluster.58 Taken together, the data
demonstrate that the quadruplex ddPCR protocol accu-
rately distinguishes between ALKF1174L, ALKR1275Q, and
wild-type ALK in plasma-derived cfDNA and tumor DNA.
Discussion
One of the challenges in infants and children with a body
weight of <10 kg is to sequentially obtain sufficient blood
volumes for molecular analyses without considerably
lowering hemoglobin levels and, ultimately, necessitating
an iatrogenically induced blood transfusion. Volumes for
blood sampling are therefore ethically restricted to 1 mL in
infants and a maximum of 3 mL in children. Experiences
with blood samples from neuroblastoma patients indicate
that, on average, 10 to 130 ng of cfDNA diluted in 50 mL
of elution buffer is available after purification for further
analysis. Previously published duplex ddPCR protocols
assessing MYCN and ALK copy numbers using NAGK as a
single reference gene each require 5 mL of cfDNA
extract.22 ddPCR is a rapid, highly sensitive, less expen-
sive, and more accessible tool for many laboratories
compared to next-generation sequencing approaches. It
enables targeted analyses of known copy number varia-
tions and mutations, while next-generation sequencing
enables an unbiased approach, but requires a longer time
to obtain, process, and analyze data, with a need for bio-
informatics expertise.59,60 Increasing evidence suggests
that the characterization of the cfDNA in plasma from
neuroblastoma patients with targeted and untargeted ap-
proaches such as ddPCR, real-time quantitative PCR,
shallow WES, OncoScan arrays (Affymetrix, Santa
Clara, CA), or WES contributes to the understanding of
molecular risk factors as well as spatial and temporal
heterogeneity in neuroblastoma.18,19,23,48,61e66
The technical feasibility of multiplexing DNA targets by
ddPCR beyond single and duplex reactions has been exem-
plarily shown by the quantification of recurrent somatic
mutations in diffuse large B-cell and follicular lymphoma
tissue sections58 and scoring programmed cell death protein1319
Peitz et alligand 1 in nonesmall cell lung cancer biopsies.67 To opti-
mize the amplitude of a droplet cluster in higher-order mul-
tiplexing assays, i) probe concentrations, ii) primer
concentrations, and iii) annealing temperature in the PCR
cycler program can be adapted.68 After optimization of the
first two parameters, simultaneous copy number assessment
of two of the major oncogenic drivers in neuroblastoma,
MYCN and ALK, was shown to be technically feasible using
NAGK and AFF3 as two normal diploid reference genes.
Quality assessment of linearity and lower limit of detection
showed highly comparable results between the respective
duplex and triplex reactions, saving precious sample volume.
While the quadruplexed ddPCR protocol was shown to be a
highly sensitive and robust analytical tool for exact assess-
ment of copy number status, it maintains a targeted analysis
by nature, which is limited to the analysis of a short range of
DNA base pairs, often of <100 nucleotides. This was re-
flected by a higher ALK amplification status in the NB-1 cell
line and by the misdetection of a partial ALK amplification in
the IMR-5 cell line due to the use of primer pairs different
from those used for previously reported data.22 Another
example of the targeted nature of the ddPCR technology was
the observation that only the WES technology but none of the
ALK ddPCR assays discriminated between a specific ALK
gain and copy number gains within the first 50 megabases of
chromosome 2p, including the ALK gene, in the neuroblas-
toma cell lines investigated. The WES data reported in the
present study are in line with those from previous studies,
summarized in Supplemental Table S1. The well-known
intrinsic ddPCR assay limitation justifies the combination
of this targeted analysis applicable in routine clinical testing
at sequential time points for monitoring disease status and the
emergence of new potentially druggable targets such as ALK
or activating Rasemitogen-activated protein kinase pathway
mutations in combination with unbiased next-generation
sequencing approaches at a defined time point, such as
initial or relapse diagnosis. Other molecular characteristics
used in neuroblastoma risk stratification, including DNA
ploidy and segmental copy number variations, are not
detected with the targetedMYCN/ALK quadruplexing ddPCR
approach. The ddPCR technology could nonetheless affect
clinical decision making by considerably shortening the time
needed for switching to a potentially promising alternative
targeted therapy, and may, therefore, have considerable po-
tential with regard to its translation into daily clinical practice
in the near future. Although the number of studies reporting
ddPCR applications in oncology has rapidly increased over
recent years, additional prospective studies in larger patient
cohorts are needed for further validation.
To increase the robustness of the ddPCR assay in the
assessment of MYCN and ALK copy number status, a
second normal diploid reference gene on the 2q arm
(AFF3 at 2q11.2) was included. The incorporation of a
second reference gene enables the internal control between
both reference genes to detect the unlikely but non-
excludable event of a potential copy number variation in a1320well-established reference gene in individual patient
samples. For example, the approximately 30% higher
MYCN and ALK copy numbers detected by triplex and
quadruplex reactions in Kelly cells were attributable to a
loss of heterozygosity in AFF3. ALK copy number
assessment in cfDNA purified from plasma samples will
enable monitoring in patients with neuroblastoma for the
targetable ALK amplification in the future. This is impor-
tant because the treatment of ALK-amplified neuroblas-
toma cell lines with ALK inhibitor was shown to potently
suppress ALK downstream signaling and to trigger an
apoptotic response in vitro.28,69 ALK amplification is
emerging as a potential biomarker associated with
response to targeted inhibition in neuroblastoma
models.15,16
The quadruplexed protocol detecting the ALK hotspot
mutations ALKF1174L (3522, C>A) and ALKR1275Q (3824,
G>A) is based on the previously reported inverted ddPCR
approach,58 and allows the successful detection and
quantification of either or both mutations in a simulta-
neous reaction in samples with low DNA input. Detection
and quantification are possible by changes in the labeled
probes and therefore measurement of ALKF1174L (3522,
C>A), together with the respective ALKwild-type sequence
in channel 1, and ALKR1275Q (3824, G>A) with this cor-
responding ALKwild-type sequence in channel 2. In this
setting, the respective mutant and wild-type sequences are
amplified with the same primer pair, and the reactions
compete against each other for the existing resources in
the droplet, diminishing the fluorescence signal from
double-positive clusters. This well-known phenomenon
from duplex reactions68 leads to a shift of the
double-positive clusters in one channel to the upper single-
positive clusters. Although the occurrence of double-
positive droplets is comparatively low in samples with
low DNA input, it increases in high-DNA input samples,
causing MAF overestimation for the respective mutation
in the calculation. Although the mutant and wild-type
sequences are detected in separate channels in duplex re-
actions and can, thereby, clearly be distinguished from
each other, the natural limitation of the inverted ddPCR
approach used here necessitates that DNA input be
restricted to maximally 20 ng, making it also well-suited
for analyzing cfDNA. Here, two novel quadruplexed
ddPCR protocols enabled, with high analytical sensitivity
and low cost, the assessment of copy number variations
and hotspot mutations crucial for monitoring and treating
children with neuroblastoma in routine clinical settings.Acknowledgments
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